Newsletter - Issue no. 1
The Jewish New Year has now begun, providing us with a great opportunity to kick-off our quarterly Alpha Tau newsletter. This last year has seen fantastic progress. The significant operational, regulatory and clinical advancement was summarised by additional funding of $29 million that was recently raised from private and VC investors. Thank you to all our investors and partners – we cannot do this without you. We look forward to working together to realize the therapeutic potential of Alpha DaRT and develop a cancer treatment that can help save the lives of millions of patients around the world. I am delighted to share with you our latest news, developments and recent activities. Enjoy the read. Uzi Sofer, CEO and Chairman, Alpha Tau Medical
The Birth of Alpha Tau Medical
How did it all start? Read our very own Co-Founder and Chief Biomedical Officer, Professor Yona Keisari’s blog, sharing his memories and clinical insights describing what sparked the birth of the Alpha Tau technology to fight cancer. Read more.
Alpha Tau Raises $29 Million from Private Financing We are delighted to have raised $29 million in private financing. The funding will be invaluable to accelerate the expansion of our global clinical research program and establish new production facilities to meet the growing demand for Alpha DaRT. I would like to thank all the investors that participated in this round; Shavit Capital, OurCrowd.com, Medison Ventures and private investors including,
Sir Ronald Cohen and Alan Patricof. Read the full PR.
FDA Has Granted IDE Approval to Commence U.S. Clinical Studies We are pleased to share that the FDA granted Investigational Device Exemption (IDE) approval, enabling Alpha Tau to commence clinical safety and effectiveness studies in the U.S. This is another significant achievement and we look forward to launching our first clinical trial with the leading cancer research institution, Memorial Sloan Kettering Cancer Center.
Alpha Tau Receives Radioactive-Safety Approval in the USA We are happy to announce that the Massachusetts Radiation Control Program (RCP), under agreement with the U.S. Nuclear Regulatory Commission (NRC), approved the treatment of Alpha DaRT, as a Sealed Source and Device (SSD). The new approval enables the initiation of clinical trials in leading cancer centers across the U.S. which are interested in investigating the Alpha DaRT as a treatment for various types of solid tumors. Read the full PR.
Expanding Presence in the USA We have now started the build of our new production facility in Lawrence, MA in the United States, following the signing of a long-term rental contract that includes options for growth and extension. Amnon Gat, Alpha Tau’s highly experienced Chief Operations Officer, has relocated from the company’s Israel headquarters to head the U.S. operations. The complicated project of building the production facility and getting all the necessary approval is expected to take several months.
We will keep you updated on our progress.
The Pathway to CE Clearance is Getting Closer We are at the final stages of applying for European CE mark. We have passed the final audit by our Notified Body, BSI, and are submitting the technical file, including our clinical data. The approval itself, enabling commercialization of the Alpha DaRT treatment in Europe, is expected in the first half of 2019."
Two New Clinical Trials Start in Rome, Italy with Leading Cancer Centers, La Sapienza and IFO We are delighted to announce we have initiated two new clinical trial protocols evaluating the efficacy of the Alpha DaRT in two leading medical centers in Rome, Italy. Following approval from the Institutional Review Board (IRB) earlier this month, La Sapienza is commencing Alpha Tau’s third clinical trial protocol for Squamous Cell Carcinoma (SCC) of the skin and oral cavity, and IFO is initiating our first study into Cutaneous and Mucosal malignant Neoplasia (CMN).
Opening Japan to the World’s First Alpha Radiation Radiotherapy for Solid Tumors We have formed a new partnership with HekaBio K.K to establish the world’s first alpha radiation brachytherapy in Japan. HekaBio K.K. is a leading developer, manufacturer and distributor of pharmaceutical products that address unmet medical needs in Japan. The new subsidiary will optimize local distribution and manufacturing of the Alpha DaRT cancer treatment in Japan.
Thank you for visiting us at ASTRO!
Prof. Aron Popovtzer presenting early promising clinical feasibility and safety results of Alpha DaRT for SCC tumors in head and neck, and skin at ASTRO- View poster Thank you to everyone for stopping by our booth earlier this month at the American Society for Radiation Oncology (ASTRO)’s 60th Annual Meeting. It was an extremely successful event with great interest shown in the clinical progress of the Alpha DaRT technology from both existing partners and new collaborations. Please contact us if you would like any further information.
Join Us at Upcoming Conferences
2018 IEEE Nuclear Science Symposium and Medical Imaging Conference, Nov. 10 - 17, Sidney, Australia
International Society of Oncology and BioMarkers, Nov. 24 - 27, Hamburg, Germany
6TH GEC-ESTRO Workshop, Nov. 29-30, Brussels, Belgium
Biotech Showcase, Jan. 7 - 9, 2019, San Francisco, USA
Alpha Tau's 1st Medical Conference
Earlier in March this year, we held our first conference with more than 200 leading medical centers from across the globe in attendance. We were delighted to receive representatives from fifty-five hospitals from twenty-three countries, who all came to discuss how the Alpha DaRT technology can be applied to various cancer indications. Thank you to everyone for your support and we hope to see you next year! Read more.
Thank you for your continued support!
It has been an exciting period at Alpha Tau and we are delighted to welcome a whole host of new partners into the Alpha Tau family. Stay tuned and don't forget to follow us on LinkedIn, Twitter and Facebook. Until next time, The Alpha Tau Team
Copyright © 2018 Alpha Tau Medical Ltd., All rights reserved. Our mailing address is: firstname.lastname@example.org